To accelerate the development of treatments for Cockayne syndrome by identifying, promoting, and/or funding intelligent, innovative, and thoughtful research proposals (including gene therapy, gene editing, and drug repurposing screens) and to connect researchers and families to advance translational research from bench to bedside.
Riaan Research Initiative Inc concentrates on a single disease target: Cockayne syndrome, with grantmaking aimed at moving research from bench to bedside. Its largest recent award was $2,198,272 to UMASS Chan Medical School in Worcester, Massachusetts, for a study of Cockayne syndrome with the ultimate aim of developing an effective gene therapy treatment. That grant aligns with the organization’s emphasis on gene therapy, gene editing, drug repurposing screens, and other translational projects that could accelerate treatment development for people with Cockayne syndrome. The foundation also backed Umass Medical School in Worcester with a $311,631 research project, showing repeated support for academic research in the same disease area. Across its active programs, Riaan Research Initiative Inc funds pre-clinical gene replacement therapy work, pilot studies, small clinical and observational projects, and research partnerships that connect scientists and families. Its stated purpose is to identify, promote, and fund intelligent, innovative, and thoughtful research proposals, including work that can inform future clinical trials and therapeutic options for a rare genetic disorder.
A core part of Riaan Research Initiative Inc’s giving is gene therapy development for Cockayne syndrome. One active program supports pre-clinical gene replacement therapy for the CSA/ERCC8 gene, with the goal of translating lab research into a human clinical trial. The foundation also funds drug repurposing work. Its research grants explicitly include drug repurposing screens as a route to treatment development, alongside broader translational projects. Another recurring theme is biomarker and clinical-study support. The organization has active studies focused on assessing GDF-15 serum levels in children with Cockayne syndrome to evaluate whether the marker may inform anti-GDF-15 antibody therapy. It also supports disease-understanding work, including natural history studies and other scientific studies related to Cockayne syndrome.
Riaan Research Initiative Inc makes relatively large project-based grants: the typical grant size is $168,316 at the 25th percentile, $311,631 at the median, and $1,254,952 at the 75th percentile. The distribution suggests a mix of mid-sized research awards and a smaller number of much larger commitments. The grant record shows repeated support to the same research institution in Worcester across multiple years, which points to ongoing disease-specific funding rather than one-off philanthropy. The foundation is structured as a grantmaking nonprofit; it does not fund individuals and does not make program-related investments. It accepts unsolicited requests for some active programs, including general research funding and certain clinical studies, while other programs are marked as not accepting unsolicited proposals.
$252K
$1.8M
$616K
$279K
Most grants fall between $168K and $1.3M, with a median of $312K.
25th Percentile
$168K
Median
$312K
75th Percentile
$1.3M
About 0% of grants go to recipients in MA.
GURJOT KAUR
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Giving is regionally concentrated but not tied to the headquarters state. No grants in the recent sample went to New York recipients, while Massachusetts is the top state by grant count. The recent grants list includes two Worcester, Massachusetts recipients, both at UMASS Chan Medical School / Umass Medical School, and one Palo Alto, California recipient, Rarebase Pbc. The recipient country distribution in the recent grants is entirely U.S.-based, with 3 grants in the United States.
It funds research on Cockayne syndrome, including gene therapy, gene editing, drug repurposing, pre-clinical research, patient registry work, and translational projects intended to move treatments toward clinical use.
Typical awards are sizable: the 25th percentile is $168,316, the median is $311,631, and the 75th percentile is $1,254,952.
Yes, for some active programs. The general research funding program and several clinical study programs accept unsolicited requests, while other programs such as the CSA gene replacement therapy project and the gene therapy research team do not.
Gene therapy is central, especially pre-clinical gene replacement therapy for the CSA/ERCC8 gene. The foundation also pairs that work with drug repurposing screens and biomarker studies such as GDF-15 assessment.
Recent grants in the dataset went entirely to U.S. recipients, with Massachusetts appearing most often. Specific recipient cities include Worcester, Massachusetts, and Palo Alto, California.
2026
Source: IRS Form 990-PF, fiscal year 2026.
Current and upcoming funding from Riaan Research Initiative that your nonprofit may be able to apply for.
Who can apply: Clinical partners with the ability to analyze serum samples from children with Cockayne syndrome and carry out a small, short study. The page asks interested parties to contact the organization.
Who can apply: Interested researchers and clinical partners working on Cockayne syndrome or related pre-clinical gene therapy research may connect with the organization; the program is centered on CSA/ERCC8 mutations and pre-clinical development.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| UMASS CHAN MEDICAL SCHOOL | WORCESTER, MA | $252,255 | 2026 | STUDY OF COCKAYNE SYNDROME WITH THE ULTIMATE AIM OF DEVELOPING AN EFFECTIVE GENE THERAPY TREATMENT |
| UMASS Chan Medical School | Worcester, MA | $2,198,272 | 2025 | Study of Cockayne Syndrome with the ultimate aim of developing an effective gene therapy treatment |
| UMASS MEDICAL SCHOOL | WORCESTER, MA | $311,631 | 2023 | RESEARCH PROJECT |
| RAREBASE PBC | PALO ALTO, CA | $25,000 | 2023 | RESEARCH PROJECT |
UMASS CHAN MEDICAL SCHOOL
$252,255STUDY OF COCKAYNE SYNDROME WITH THE ULTIMATE AIM OF DEVELOPING AN EFFECTIVE GENE THERAPY TREATMENT
UMASS Chan Medical School
$2,198,272Study of Cockayne Syndrome with the ultimate aim of developing an effective gene therapy treatment
UMASS MEDICAL SCHOOL
$311,631RESEARCH PROJECT
RAREBASE PBC
$25,000RESEARCH PROJECT
